药康生物(688046) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥135,914,412.02, representing a year-over-year increase of 34.21%[6] - The net profit attributable to shareholders for Q3 2022 was ¥46,491,112.41, reflecting an 18.98% increase compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥23,181,972.53, up 38.50% year-over-year[6] - The increase in net profit for the year-to-date period was attributed to higher sales revenue and increased government subsidies compared to the previous year[18] - The company's net profit attributable to shareholders increased to ¥257,969,402.05, compared to ¥129,843,276.84 in the same period last year, marking a growth of 99%[38] - The company's net profit for the third quarter of 2022 was CNY 128,126,125.21, an increase of 50.0% compared to CNY 85,416,398.54 in the same period of 2021[41] - The total comprehensive income for the third quarter was CNY 128,816,522.89, compared to CNY 85,949,159.59 in the same quarter of the previous year, marking a growth of 49.8%[42] Research and Development - Research and development expenses for Q3 2022 totaled ¥22,921,127.94, a significant increase of 58.79% compared to the same period last year[10] - The company plans to continue expanding its R&D efforts, focusing on large-scale projects such as "spot mice" and "real-world animal models" to drive future growth[20] - Research and development expenses amounted to ¥61,531,906.43, a significant rise of 62% from ¥38,097,614.91 in the previous year[38] Assets and Equity - Total assets at the end of Q3 2022 reached ¥2,198,953,073.60, marking a substantial increase of 108.55% from the end of the previous year[10] - The equity attributable to shareholders at the end of Q3 2022 was ¥1,940,551,703.82, which is a 147.00% increase compared to the previous year-end[10] - Total assets reached ¥2,198,953,073.60, up from ¥1,054,409,220.49, reflecting a growth of 108%[36] - The company's equity attributable to shareholders increased to ¥1,940,551,703.82, compared to ¥785,633,044.20, a growth of 147%[38] Shareholder Information - Total number of common shareholders at the end of the reporting period was 5,958[21] - The largest shareholder, Nanjing Laoyan Venture Capital Partnership, holds 201,817,185 shares, accounting for 49.22% of total shares[21] - The second largest shareholder, Qingdao Guoyao Dachuang Investment Partnership, holds 34,745,078 shares, representing 8.47%[21] - The top ten shareholders include various investment funds, with the largest being China Industrial Bank's mixed securities investment fund holding 6,606,462 shares[26] - The company has not disclosed any significant related party transactions among the top ten shareholders[28] Cash Flow and Financial Stability - The company's cash and cash equivalents as of September 30, 2022, amounted to ¥355,857,001.38, an increase from ¥293,517,395.01 at the end of 2021[30] - Cash and cash equivalents increased significantly, contributing to improved liquidity and financial stability[36] - Cash flow from operating activities generated a net inflow of CNY 46,996,531.16, an increase from CNY 37,986,022.69 in the prior year[47] - The company reported a significant increase in cash and cash equivalents, ending the quarter with CNY 355,757,001.38, compared to CNY 187,105,204.79 at the end of the same quarter last year[49] - Investment activities resulted in a net cash outflow of CNY 990,833,403.54, compared to a smaller outflow of CNY 390,365,635.46 in the previous year[49] - The company received CNY 1,029,513,457.49 from financing activities, indicating strong capital inflow compared to CNY 25,000,000.00 in the same period last year[49] Operating Costs - Total operating costs for the first three quarters of 2022 were ¥285,523,134.45, up from ¥202,941,108.39, reflecting a 41% increase[38] - Accounts receivable rose to ¥190,355,407.96, compared to ¥118,571,037.55, indicating an increase of 60%[33] - Inventory increased to ¥46,586,371.56 from ¥30,083,605.37, representing a growth of 55%[33] Financial Statements and Caution - The financial statements for the quarter are unaudited, indicating a need for caution in interpreting the results[29] - The company has not participated in any margin trading or securities lending activities as per the information available[28] - The company reported a decrease in credit impairment losses, which improved to CNY -4,869,853.19 from CNY -6,828,585.99 in the previous year[41]